1Associate Professor and HOD, Department of Kaumarbhritya, Gomantak Ayurveda Mahavidyalaya and research, Centre, Shiroda, Goa- 403103.
2Associate Professor & HOD, Dept of Kaumarbhritya, R. A. Podar Medical College & M. A. Podar Hospital, Worli, Mumbai, Maharashtra- 400018.
*Corresponding author: Dr. Sumod Khedekar, Associate Professor and HOD, Department of Kaumarbhritya, Gomantak Ayurveda Mahavidyalaya and research, Centre, Shiroda, Goa- 403103. Email Id: vaidya.sumod@gmail.com
Received: 12th Dec, 2025; Revised: 12th Feb 2026; Accepted: 13th Feb, 2026; Available Online: 10th March, 2026
Background: Recurrent respiratory tract infections (RRTIs) associated with Type I hypersensitivity represent a major cause of Pediatric morbidity and healthcare burden worldwide. Existing pharmacological interventions offer symptomatic relief but are often associated with adverse effects and limited immunomodulatory potential, highlighting the need for safe, long-term therapeutic options.
Objective: To evaluate IgE-associated immunomodulatory effects of Bal-Rasayana® Syrup, a polyherbal formulation, in Pediatric patients with recurrent respiratory tract infections associated with Type I allergy.
Methods: This open-label, non-comparative, prospective clinical study (CTRI Registration No. CTRI/2024/05/067252) was conducted at a tertiary care teaching hospital in Mumbai, India, in accordance with CONSORT guidelines. Thirty-two children aged 3–16 years with recurrent respiratory tract infections associated with Respiratory allergy and showing classical symptoms of Vataja Pratishyaya were enrolled. Bal-Rasayana® Syrup was administered orally for 60 days, with dosage determined according to Young's formula. Clinical assessments were performed at baseline and at 15-day intervals, with a post-treatment follow-up on Day 90.
Results: All subjective clinical parameters showed statistically significant improvement after treatment (p < 0.01), with sneezing demonstrating a highly significant reduction (p < 0.001). Comparison of Before Treatment (BT) and After Treatment (AT) values in the trial group revealed highly significant changes in objective parameters, including serum IgE levels, absolute eosinophil count, and hemoglobin percentage (p < 0.001 for all). No treatment-related adverse events were reported during the study period.
Conclusion: Bal-Rasayana® Syrup demonstrated significant IgE-associated immunomodulatory effects in children with recurrent respiratory tract infections and Type I allergy, with a favourable safety profile. The findings suggest that Bal-Rasayana® Syrup offers a holistic and sustainable therapeutic alternative to conventional management in Pediatric Recurrent respiratory tract infections.
Keywords: Bal-Rasayana® Syrup; Ayurveda, Pediatric Allergy; Recurrent Respiratory Tract Infections; Type I Hypersensitivity; Immunomodulation.
How to cite this article: Khedekar S, Thakur SK. Evaluation of IgE-Associated Immune Modulation of Bal-Rasayana® Syrup in Pediatric Recurrent Respiratory Tract Infections with Type I Allergy. Int J Drug Deliv Technol. 2026;16(16s): 597-602. DOI: 10.25258/ijddt.16.16s.65
Source of support: Nil.
Conflict of interest: None